Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs

European Journal of Medicinal Chemistry

Volumn 126, Issue , 2017, Pages 154-159

  Stachulski, Andrew V ^a   Swift, Karl ^b   Cooper, Mark ^b   Reynolds, Stephen ^b   Norton, Daniel ^c   Slonecker, Steven D ^c   Rossignol, Jean François ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Bio techne Tocris Bioscience IO Centre   (United Kingdom)

^c Calvert Laboratories Inc   (United States)

^d Romark Laboratories   (United States)

Author keywords

Antiviral agents; Biodisposition; Chemical synthesis; Oral absorption; Pharmacology; Prodrugs; Stability; Toxicology

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; NITAZOXANIDE; PRODRUG; RM 4848; RM 5038; RM 5061; RM 5064; THIAZOLE DERIVATIVE; THIAZOLIDE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG; [2 [(5 CHLORO 1,3 THIAZOL 2 YL)CARBAMOYL]PHENYL] 2 AMINO 3,3 DIMETHYLBUTANOATE; [2 [(5 NITRO 1,3 THIAZOL 2 YL)CARBAMOYL]PHENYL] 2 AMINO 3,3 DIMETHYLBUTANOATE; ESTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; MALE; NONHUMAN; PRECLINICAL STUDY; RAT; RESPIRATORY FUNCTION; SINGLE DRUG DOSE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; METABOLISM; ORTHOMYXOVIRIDAE; PARAMYXOVIRIDAE; PHYSIOLOGY; SAFETY; SYNTHESIS; VIRUS REPLICATION;

AMINO ACIDS; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG EVALUATION, PRECLINICAL; ESTERS; FEMALE; MALE; ORTHOMYXOVIRIDAE; PARAMYXOVIRIDAE; PRODRUGS; RATS; SAFETY; THIAZOLES; VIRUS REPLICATION;

EID: 84992128569     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.09.080     Document Type: Article

References (27)

1. [1] Rossignol, J.-F., Cavier, R., 2-Benzamido-5-Nitrothiazoles. Chem. Abstr., 83, 1975, 28216n.
2. [2] Rossignol, J.-F., Maisonneuve, H., Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana. Am. J. Trop. Med. Hyg. 33 (1984), 511–512.
3. [3] Doumbo, O., Rossignol, J.-F., Pichard, E., Traore, H., Dembele, M., Diakite, M., Traore, F., Diallo, D., Nitazoxanide in the treatment of cryptosporidial diahorrea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56 (1997), 637–639.
4. [4] Rossignol, J.-F., Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate programme in 365 patients. Aliment. Pharmacol. Ther. 24 (2006), 887–894.
5. [5] Fox, L.M., Saravolatz, M.D., Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40 (2005), 1173–1180.
6. [6] Hoffman, P.S., Sisson, G., Croxen, M.A., Welch, K., Harman, W.D., Cremades, N., Morash, M.G., Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 51 (2007), 868–876.
7. [7] Atherton, R.R.D., Mechanism of Action of Nitazoxanide and Related Drugs against Helminths. Thesis submitted for the degree of Doctor of Philosophy of the University of London, 2003.
8. [8] De Carvalho, L.P.S., Dardy, C.M., Rhee, K.Y., Nathan, C., Nitazoxanide disrupts membrane potential and Intrabacterial homeostasis of Mycobacterium tuberculosis. ACS Med. Chem. Lett. 2 (2011), 849–854.
9. [9] Müller, J., Arunasalam, N., Müller, N., Hemphill, A., Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol. 118 (2008), 80–88.
10. [10] Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.G., Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J. Biol. Chem. 284 (2009), 29798–29808.
11. [11] Piacentini, S., La Frazia, S., Rossignol, J.F., Santoro, G., Antiviral activity of nitazoxanide against paramyxoviridae infection: effect on the fusion (F) protein. Oral Presentation at the XVIII International Symposium on Respiratory Viral Infections, 2016, The Macrae Foundation, Lisbon, Portugal March 31- April 2.
12. [12] Stachulski, A.V., Pidathala, C., Row, E.C., Sharma, R., Berry, N.G., Iqbal, M., Bentley, J., Allman, S.A., Edwards, G., Helm, A., Hellier, J., Korba, B.E., Semple, J.E., Rossignol, J.-F., Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. J. Med. Chem. 54 (2011), 4119–4132.
13. [13] Stachulski, A.V., Pidathala, C., Row, E.C., Sharma, R., Berry, N.G., Lawrenson, A.S., Moores, S.L., Iqbal, M., Bentley, J., Allman, S.A., Edwards, G., Helm, A., Hellier, J., Korba, B.E., Semple, J.E., Rossignol, J.-F., Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J. Med. Chem. 54 (2011), 8670–8680.
14. [14] Korba, B.E., Montero, A.B., Farrar, K., Gaye, K., Mukerjee, S., Ayers, M.S., Rossignol, J.F., Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir. Res. 77 (2008), 56–63.
15. [15] Rossignol, J.F., Nitazoxanide, a first-in-class broad-spectrum antiviral agent. Antivir. Res. 110 (2014), 94–103.
16. [16] Rossignol, J.-F., Abu-Zekry, M., Hussein, A., Santoro, M.G., Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomized double-blind placebo-controlled trial. Lancet 368 (2006), 124–129.
17. [17] Haffizula, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., Rossignol, J.-F., Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomized, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 14 (2014), 609–618.
18. [18] Rossignol, J.F., Elfert, A., El-Gohary, Y., Keefe, E.B., Improved virologic response in chronic hepatitis C genotype 4. Patients given nitazoxanide, peginterferon and ribavirin. Gastroenterology 136 (2009), 856–862.
19. [19] Rossignol, J.-F., Stachulski, A.V., Syntheses and antibacterial activites of tizoxanide, an N-(Nitrothiazolyl)salicylamide, and its O-aryl glucuronide. J. Chem. Res. (S), 1999, 44–45.
20. [20] Broekhuysen, J., Stockis, A., Lins, R.L., De Graeve, J., Rossignol, J.F., Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38 (2000), 387–394.
21. [21] Rauutio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., Savolainen, J., Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7 (2008), 255–270.
22. [22] Beauchamp, L.M., Orr, G.F., Demiranda, P., Burnette, T., Krenitsky, T., A., Amino-acid ester prodrugs of acyclovir. Antivir. Chem. Chemother. 3 (1992), 157–164.
23. [23] Guo, A., Hu, P., Balimane, P.V., Leibach, F.H., Sinko, P.J., Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 289 (1999), 448–454.
24. [24] Tertiary leucine has not infrequently been incorporated into peptide sequencesGalande, A.K., Bramlett, K.S., Trent, J.O., Burris, T.P., Wittliff, J.L., Spatola, A.F., Potent inhibitors of LXXLL-based protein-protein interactions. Chem. Bio. Chem. 6 (2005), 991–1998.
25. [25] Yu, S.-W., Lee, H.-Y., Cho, B.-H., An, K.-M., Ryu, J.-S., Lee, Y.-H., Kang, J.-H., Synthesis and biological evaluation of N-formyl hydroxylamine derivatives as potent peptide deformylase inhibitors. Bull. Korean Chem. Soc. 27 (2006), 1075–1078.
26. [26] Raju, V.V.N.K.V.P., Vedantham, R., Khunt, M.D., Mathad, V.T., Dubey, P.K., Chakravarthy, A.K., An efficient and large scale process for synthesis of valacyclovir. Asian J. Chem. 22 (2010), 4092–4098.
27. [27] The stability of valacyclovir has been studied over a wide pH rangeGranero, G.E., Amidon, G.L., Stability of valacyclovir: implications for its oral bioavailability. Int. J. Pharm. 317 (2006), 14–18.